The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Possibly a takeover target as well, either big US or venture Cap co?
Let’s hope following the Mail article, results will include a very positive statement on the year ahead.
This ship is moving at last could we see a delayed movement after all defence cos have made highs?
Hmmm... The RNS is a pretty uninspiring piece. It seems to be saying "More of the same, hopefully". The previous revision to forecasts did the damage and this latest update hasn't got anything to reverse it. Ah well, back to sleep for the management team.
QQ, BA.all up. Is management asleep?
Times such as these, the MOD and affiliates will be expected to spend more with less scrutiny on product/services, suspect this is the reason. BAE went up by 12% or more in the past 2 days. Avon Protection similarly has risen.
Assume the recovery is based on the military aspects of the business. Anyone expect increasing sales in areas we operate in?
Disappointing performance at 2 subsidiaries that make it look as though group executives had their eye off the ball. The consequent large sp pull-back today offers great buying opportunities for lth, but I will wait a few days to see how it settles.
Anyone got any inkling of the date of the CHRT half year update? Their investor relations page just says "December 2021".
Cheers.
I agree , and each order ( like this mornings RNS ) help us on our way .
new edition of Tip newsletter out on Sat 31st , possible updates on GFIN, CHRT, CER,D4T4
Latest sp prediction for next year 623.012p and longterm 1019.52p
Cohort would have been a good purchase at the price when this was posted. Unfortunately I paid 620p when I bought in so it's been a poor investment for me. Fingers crossed for the results next week but I'll probably be selling if I see the SP rise much before the 27th.
Results due on 27th July. Similar shares in sector like Darktrace and Panolpy have had strong preformances .
Im thinking the sp here looks too cheap
pros-
2% Div yield and growing annually
200m market cap but only 6m of debt
UK defense spending looks secure
Potential for growth
Risks -
increasing red tape for the sector
supply chain issues
SP has dropped significantly in last year.
I would be pleased to hear more thoughts?
That would be good, but remember share prices usually fall after they have gone ex-dividend
now down c25% since mid may on very thin volume. Results due 27/7. Looks way more upside than downside to me.
https://markets.ft.com/data/equities/tearsheet/forecasts?s=CHRT:LSE
The FT says target range 675p-690p according to broker analysis + another 11% increase in dividend expected.
CHRT should be following Darktrace (DARK) as they post their results today, with an upgraded forecast and 3 % rise in SP
althogh was up by over 10% during the day, before profit taking . Shares up about 30% in the last month.
Share price is finally on the way up.
Su h a quiet board. €49m contract win announced by RNS today. Significant marker which is likely to lead to further wins. After recent sp fall back this looks very cheap imo.
Target SP still after recent falls is 681.061p
Those that follow Techinvest, next edition out shortly.
CER has a 1 year target price of 1229.33p currently around 885p.
R1 593.752p
R2 600.503p
R3 614.007p
S1 573.497p
S2 559.993p
S3 553.242p
https://markets.ft.com/data/equities/tearsheet/forecasts?s=CHRT:LSE#:~:text=Share%20price%20forecast,the%20last%20price%20of%20604.00.
min target 675p 2 brokers say buy.